Greetings,
Every Monday afternoon, we send out a stock trade idea to some of MarketBeat's best and most valued subscribers.
We think you are one of those people...but you are not on our alert distribution list yet.
This once a week alert is sent out via SMS so that you can see it right away.
Last week's alert was very popular with our subscribers, you won't want to miss out on the next alert -- and it doesn't cost you a thing.
We're going to send out another trade idea on Monday around noon, and I want to make sure that you're able to see it.
Add your name to the distribution list here.
You'll thank me on Tuesday morning.
Matthew Paulson
MarketBeat
3 Stocks Under $5 With Strong Analyst Upside Potential
Written by Chris Markoch. Originally Published: 2/24/2026.
Key Points
- Grab Holdings is gaining analyst support as revenue growth and its first full year of profitability highlight long-term opportunity in Southeast Asia’s expanding digital economy.
- Vaxart offers speculative biotech upside with its oral vaccine platform targeting influenza, norovirus, and COVID-19, creating a high-risk, high-reward setup.
- ThredUp is positioned to benefit from the fast-growing resale market, with strong institutional ownership and industry forecasts pointing to sustained secondhand demand.
- Special Report: [Sponsorship-Ad-6-Format3]
While many investors are rotating out of speculative penny stocks, others continue to embrace the risk-reward dynamic. Stocks trading under $5 carry significant risk: many of these companies are unprofitable, and some generate little to no revenue.
These are typically small-cap companies, a segment that has been beaten up in recent years. Even with the Russell 2000 showing some signs of recovery, that improvement hasn't been broad-based across the small-cap sector.
Skip Headlines Straight to Original Research (Ad)
Our investment research analysts are going to be releasing their next investment idea tomorrow morning, around 10:00 AM Eastern time.
Add yourself to the distribution list here.That could change in 2026 if the economic outlook continues to improve, potentially drawing money back into speculative names. As with any market segment, though, quality matters.
One way to filter for quality is to favor names with positive analyst sentiment. These three stocks fit that description. Each allows investors to start a sizable position with a modest outlay while still offering the potential for meaningful upside over the next five years.
Profitability Milestone Meets Long-Term Emerging Market Growth
Emerging market stocks are expected to be among the winners in 2026, though that hasn't been the case so far for Grab Holdings Inc. (NASDAQ: GRAB), which is down about 15% this year. Based in Singapore, Grab operates a super app that blends technology, e-commerce and fintech services.
Part of the recent pullback stems from its proposed merger with Indonesian ride-share competitor Go To. The deal is not final and could face significant legislative changes in Indonesia that might limit the company's earnings potential there.
Grab also missed the top line in its Q4 2025 earnings report. Still, revenue rose 19% year-over-year (YOY), and 2025 marked the company's first full year of profitability. Analysts are forecasting roughly 120% earnings growth over the next 12 months.
That helps explain why sentiment remains bullish. GRAB has a consensus price target of $6.47, about 54% above its current level.
High-Risk Biotech With Platform Potential
Penny-stock investors often look to the biotechnology sector to balance risk and reward. One name to watch is Vaxart Inc. (OTCMKTS: VXRT), the only company on this list that fits the classic penny-stock definition. At the time of writing, it traded just above $0.60 per share.
VXRT lacks heavy analyst coverage, but the sole analyst rating in the past 12 months is a Buy with a $2 price target.
That limited coverage isn't uncommon for clinical-stage biotechs—Vaxart's candidates are still in clinical trials. The upside, however, is clear: the company is developing oral vaccines targeting influenza, norovirus and COVID-19.
Beyond convenience and avoiding needles, Vaxart says its oral platform may induce a broader immune response and broader protection.
Institutional ownership is only about 18%, but in terms of dollar volume, inflows outnumber outflows nearly 10:1, which is notable for such a small-cap, clinical-stage name.
Resale Tailwinds Could Turn Today's Losses Into Tomorrow's Gains
ThredUp Inc. (NASDAQ: TDUP) is down about 33% in 2026, but a longer view shows the stock up more than 66% over the last 12 months. That suggests the recent drop may be a pullback amid a market that's shunning companies not yet profitable.
ThredUp operates an online consignment and thrift platform that has gained traction with Gen Z. In its most recent quarter, revenue rose 12.5% YOY.
The company cites a GlobalData 2025 Market Survey forecasting the U.S. secondhand market's gross merchandise value to grow at a compound annual growth rate (CAGR) of 9% through 2029.
Institutions own roughly 89% of TDUP. Dollar buying has outpaced selling about 2:1, and buyer/seller counts are about 3:1. That said, short interest of around 17% can add near-term volatility.
The consensus price target from six analysts is $12.50, which would represent roughly a 190%+ upside from the price at the time of writing.
IonQ in Rebound Mode: Buy the Thesis, Respect the Risk
Written by Thomas Hughes. Originally Published: 3/3/2026.
Key Points
- IonQ's fiscal Q4 results beat expectations, but the stock's path forward depends on more than just one strong quarter.
- A major acquisition and surging government-adjacent demand could reshape the company's trajectory—if execution follows through.
- Institutional buying and elevated short interest are setting up a potential technical catalyst, though analysts aren't fully on board yet.
- Special Report: [Sponsorship-Ad-6-Format3]
IonQ's (NYSE: IONQ) Q4 2025 earnings report may or may not signal a shift in the broader quantum narrative. What it does show is demand for its services and execution of its strategy, putting the company on a path to potentially lead the industry. The strategy is refocused on the chips that drive quantum, a full-stack approach, and a unified platform for users. Key details include strong revenue and guidance, and a potential stock-price rebound that could add as much as 80% to 100%.
There are clear risks. The underlying technology, while revenue-generating, is still in early development. IonQ is not yet profitable, burns cash, and may need to issue shares in future years. A 2025 share offering left the company well-capitalized, but shares outstanding increased by about 70% year over year, so any equity gains could be ephemeral. Most of the cash is earmarked for technology investment, expansion, and acquisitions, and operational losses remain a concern—so the cash position could shrink quickly.
Elon Musk already made me a "wealthy man" (Ad)
I Met Elon Musk "Face-to-Face"
During a private gathering of Wall Street elites, I was one of two people selected to speak with Elon personally.
As a result, my research now leads me to believe Elon will announce the SpaceX IPO on this date:
March 26, 2026. Circle it on your calendar.
I'm sharing an "access code" that lets anyone grab a pre-IPO stake before it happens. This is your invitation to the biggest wealth-building event of the decade.
The acquisition pipeline includes SkyWater Technologies. Valued at $1.8 billion in cash and stock, the deal adds domestic foundry and development capabilities, giving IonQ greater supply-chain control. SkyWater also brings existing clients and revenue that could accelerate IonQ's timeline toward commercialization.
Analysts Respond Favorably: Limit IonQ Upside in 2025
The analysts' reaction to the Q4 results was broadly bullish, citing large revenue outperformance, a growing backlog, and a constructive guide. Yet they did not aggressively lift price targets. The six revisions MarketBeat tracked in the first week after the release included four price-target reductions and one new target; overall, the targets clustered at the low end of the range. That activity can limit near-term upside, potentially capping gains around consensus, but it doesn't eliminate rebound potential: the stock could rise 20% to 50% relatively quickly given other factors.
Institutional and short-selling data suggest a possible short-covering rally or squeeze. The short interest is down from its peak but rose sequentially in the latest report, remaining near long-term highs at about 25%. That is a meaningful headwind and could cap gains, but institutional buying provides offsetting support. Institutions own more than 40% of the stock and have been net buyers in recent quarters.
MarketBeat data show the institutions are buying at a pace of more than $3 of purchases for every $1 of sales, with overall activity ramping to record levels in early Q1 2026. This broad-based institutional support—beyond passive index flows—helps form a solid base and can be a tailwind for the shares during a rebound. Technically, the market looks well-supported, with rising volume as prices advanced.
Long Path to Profits Raises Risks for Investors
Q4 results were solid and analysts are raising their estimates. Near- and long-term forecasts improved, but a major hurdle remains: profitability. IonQ is expected to improve its leverage over time, yet profits are not projected until well into the next decade. That timeline leaves the share price exposed to volatility, execution risk, and disruption. The company will need near-flawless execution—any delay or setback will likely be reflected quickly in the stock's performance, as chart action shows.
Disruption could come from a pure-play competitor, but it's more likely to come from one of the large tech blue chips that can absorb long investment horizons. For example, NVIDIA (NASDAQ: NVDA), which collaborates with IonQ on integration, has ample cash and could acquire IonQ multiple times over while continuing to execute its core strategies, including integrating quantum with classical systems.
Other Magnificent Seven names—Alphabet (NASDAQ: GOOGL) and Microsoft (NASDAQ: MSFT) among them—are also investing heavily in quantum. Alphabet is often seen as the biggest threat, focusing on fault-tolerant systems and its Willow chip. Released at the end of 2024, Willow represents a meaningful advance, showing improved error reduction as systems scale.
This email message is a sponsored message provided by MarketBeat Alerts, a third-party advertiser of InsiderTrades.com and MarketBeat.
If you have questions or concerns about your subscription, feel free to email MarketBeat's U.S. based support team at contact@marketbeat.com.
If you no longer wish to receive email from InsiderTrades.com, you can unsubscribe.
© 2006-2026 MarketBeat Media, LLC.
345 N Reid Pl., Sixth Floor, Sioux Falls, South Dakota 57103. United States of America..
Comments
Post a Comment